Recent progress on tyrosine kinase 2 JH2 inhibitors.

Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family, which can regulate the signaling of multiple pro-inflammatory cytokines, including IL12, IL23 and type I interferon (IFNα/β), and its inhibitors can treat autoimmune diseases caused by the abnormal expression of IL12 and IL23. Interest in TYK2 JH2 inhibitors has increased as a result of safety concerns with JAK inhibitors. This overview introduces TYK2 JH2 inhibitors that are already on the market, including Deucravactinib (BMS-986165), as well as those currently in clinical trials, such as BMS-986202, NDI-034858, and ESK-001. Copyright © 2023 Elsevier B.V. All rights reserved.

Citation

Lidan Deng, Li Wan, Tingting Liao, Lin Wang, Jie Wang, Xianbo Wu, Jianyou Shi. Recent progress on tyrosine kinase 2 JH2 inhibitors. International immunopharmacology. 2023 Aug;121:110434

Mesh Tags

Substances

PMID: 37315371

search → result